T-cell based immunotherapy for melanoma and understanding how TLR/IL-1 receptor-associated kinase (IRAK) signal pathway in cancer contributes to cancer progression and chemotherapy resistance.
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.